XML 67 R49.htm IDEA: XBRL DOCUMENT v3.20.4
Revenue - Janssen Biotech Agreement (Details) - USD ($)
$ in Thousands
1 Months Ended 3 Months Ended 12 Months Ended
Feb. 28, 2018
Dec. 31, 2020
Sep. 30, 2020
Jun. 30, 2020
Mar. 31, 2020
Dec. 31, 2019
Sep. 30, 2019
Jun. 30, 2019
Mar. 31, 2019
Dec. 31, 2020
Dec. 31, 2019
Dec. 31, 2018
Collaborative Arrangements and Co-Promote Agreement                        
Revenues   $ 18,730 $ 18,257 $ 15,008 $ 19,862 $ 29,499 $ 12,427 $ 26,150 $ 5,338 $ 71,857 $ 73,414 $ 60,370
Percentage of profit share 33.00%                 35.00%    
Revenue from collaborative arrangements                   $ 26,464 31,245 130
Research and development                   260,953 219,248 201,348
Janssen                        
Collaborative Arrangements and Co-Promote Agreement                        
Upfront payment receivable $ 100,000                 100,000    
Percentage of profit share 67.00%                      
Maximum potential payments receivable $ 900,000                      
Revenue from collaborative arrangements                   26,426 31,096 31,053
Deferred revenue   $ 11,400               11,400    
Research and development                   $ 38,500 $ 39,900 $ 38,600
Janssen | Collaborative Arrangement                        
Collaborative Arrangements and Co-Promote Agreement                        
Upfront payment receivable 100,000                      
Revenues 700,000                      
Collaborative arrangement, future development and commercialization milestones 700,000                      
Janssen | Collaborative Arrangement | TD-1473                        
Collaborative Arrangements and Co-Promote Agreement                        
Collaborative arrangement, opt in fee $ 200,000